Promising new combo offers hope for rare, aggressive ovarian cancer
NCT ID NCT04602377
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can improve outcomes for people with a rare and aggressive ovarian cancer called small cell ovarian carcinoma of hypercalcemic type. The trial aims to increase the chance of complete remission and allow more patients to receive intensive chemotherapy. About 27 participants aged 12 and older with untreated disease will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Limoges - Hôpital Dupuytren
RECRUITINGLimoges, 87042, France
-
Centre Georges François Leclerc
ACTIVE_NOT_RECRUITINGDijon, 21079, France
-
Centre Hospitalier Régional Universitaire de Besançon
ACTIVE_NOT_RECRUITINGBesançon, 25030, France
-
Centre Hospitalier Universitaire d'Angers
ACTIVE_NOT_RECRUITINGAngers, 49933, France
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
-
Centre Oscar Lambret
ACTIVE_NOT_RECRUITINGLille, 59020, France
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Hôpital de Hautepierre
NOT_YET_RECRUITINGStrasbourg, France
-
ICANS - Institut de cancérologie Strasbourg Europe
RECRUITINGStrasbourg, 67033, France
-
ICM Val d'Aurelle
WITHDRAWNMontpellier, 34298, France
-
ICO - Paul Papin
RECRUITINGAngers, 49055, France
-
Institut Bergonié
ACTIVE_NOT_RECRUITINGBordeaux, 33076, France
-
Oncopole Claudius Regaud - IUCT Oncopole
RECRUITINGToulouse, 31059, France